The drug development firm Vernalis has reported a successful outcome in Phase I trials of its V81444 treatment that may be useful in the fight against Parkinson's disease.
The double-blind, placebo-controlled study showed "a wide range of doses were found to be well tolerated with no unexpected safety findings."
The focus now shifts to a "receptor occupancy" study, scheduled to start in the second half of 2012.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
By 11:19 Vernalis shares had risen 1.4%.
BS
-
Are you one of 15 million people at risk of retirement poverty?Two-fifths of people in the UK aren’t on track for a minimum lifestyle in retirement, new data shows. Are there steps you can take to boost your pension?
-
150 banking hubs now open across UK – is there one near you?As the 150th banking hub opens its doors, a Post Office deal that offers basic banking services has also been extended until 2030. We explain what this means for you
